Cetrelimab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cetrelimab
Accession Number
DB15421
Description

Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).

Type
Biotech
Groups
Investigational
Synonyms
  • Cetrelimab
  • JNJ-63723283

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
LYK98WP91F
CAS number
2050478-92-5

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentUrinary Bladder Neoplasms1
2RecruitingTreatmentAggressive Variant Prostate Carcinoma / Castration-Resistant Prostate Carcinoma / Metastatic Hormone Refractory Prostate Cancer / Metastatic Prostate Neuroendocrine Carcinoma / Metastatic Prostate Small Cell Carcinoma / Stage IV Prostate Cancer AJCC v81
2RecruitingTreatmentUrinary Bladder Neoplasms1
2, 3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1Active Not RecruitingTreatmentCastration-Resistant Prostatic Neoplasms1
1RecruitingTreatmentNeoplasms1
1, 2Active Not RecruitingTreatmentNeoplasms1
1, 2RecruitingTreatmentProstatic Neoplasms, Castration-Resistant1
1, 2RecruitingTreatmentTransitional Cell Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 15:28 / Updated on February 21, 2021 18:55